Markus Hufnagel
Expertise in
10
conditions

Markus Hufnagel

Freiburg, BW, DE 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
10
conditions
Freiburg, BW, DE 

Overview

Markus Hufnagel practices practicing medicine in Freiburg, Germany.

Mr. Hufnagel is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Juvenile Idiopathic Arthritis (JIA), Familial Mediterranean Fever, Arthritis, and Infantile Neutropenia.

He is actively involved in clinical research, co-authoring 101 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Freiburg, BW, Germany
Other Locations
Koeln, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: May 12, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drugs: Ixekizumab, Adalimumab
Study Phase: Phase 3
View 1 Less Clinical Trial

99 Total Publications

Bacterial Pathogens and Antibiotic Resistance Patterns in Pediatric Appendicitis: Implications for Antibiotic Choice.
Bacterial Pathogens and Antibiotic Resistance Patterns in Pediatric Appendicitis: Implications for Antibiotic Choice.
Journal: The Pediatric infectious disease journal
Published: February 24, 2026

Frequently Asked Questions about Markus Hufnagel

Is Markus Hufnagel a top-rated expert for Juvenile Idiopathic Arthritis (JIA)?

MediFind is an objective health platform that identifies experts based on real-world data. Markus Hufnagel is classified as an Distinguished expert for Juvenile Idiopathic Arthritis (JIA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Markus Hufnagel participate in research or clinical trials?

Yes. Markus Hufnagel has published 99 articles and abstracts on conditions like Juvenile Idiopathic Arthritis (JIA). You can view a list of Markus Hufnagel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hufnagel's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 33 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile